A phase 3 trial evaluating sotatercept-csrk (Winrevairâ„¢) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...
The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.